EP300 and prostate cancer: They demonstrated that NEO2734, a dual inhibitor targeting both BRD4 and p300, suppresses CD318 transcription and its downstream signaling pathways, thereby inhibiting proliferation and metastasis in castration-resistant prostate cancer cells [47].